Kerry Group has announced the opening of its newly expanded biotechnology manufacturing facility in Carrigaline, County Cork, marking a significant milestone in the company’s efforts to scale up the production of lactase enzymes for the global dairy industry. This strategic investment reflects Kerry’s long-term commitment to biotechnology innovation and its role in supporting the rapidly growing demand for lactose-free and sugar-reduced dairy products worldwide.
The upgraded facility substantially increases Kerry’s industrial-scale production capacity for lactase enzymes—key ingredients used to break down lactose into simpler sugars, enabling the creation of lactose-free dairy products that maintain their natural taste and nutritional value. As consumer awareness around digestive health and sugar reduction continues to rise, dairy producers are under increasing pressure to deliver products that meet these evolving preferences without compromising quality. Kerry’s expansion directly addresses this need by enabling faster, more efficient, and reliable enzyme supply at commercial scale.
According to Shane McGibney, President and CEO of Biotechnology Solutions and Transformation at Kerry, the investment represents the culmination of decades of scientific research and development translated into practical, scalable solutions. He emphasized that the expanded facility strengthens the connection between enzyme engineering and industrial manufacturing, allowing innovations developed in the lab to be rapidly deployed in real-world production environments. This integrated approach helps customers accelerate product development timelines while ensuring consistency and performance at scale.
The Carrigaline expansion also reinforces Kerry’s broader biotechnology ecosystem, which integrates advanced research, development, and manufacturing capabilities across multiple global locations. At the center of this network is the company’s Global Innovation Centre, which serves as a hub for application development and customer collaboration. This is complemented by specialized biotechnology expertise at the Kerry Biotechnology Centre in Leipzig, Germany, where enzyme engineering and strain development are carried out. By linking these capabilities with the expanded production infrastructure in Ireland, Kerry has created a seamless pipeline that accelerates the journey from scientific discovery to commercial application.
This coordinated global approach allows Kerry to provide end-to-end support for its customers, from initial enzyme selection and product formulation to process optimization and full-scale manufacturing. The result is a more agile and responsive system that reduces development bottlenecks and enhances supply chain resilience. For dairy producers, this means faster time-to-market and greater confidence in meeting consumer demand for innovative dairy solutions.
The importance of the Carrigaline facility extends beyond Kerry’s own operations, playing a key role in strengthening Ireland’s position as a hub for advanced food manufacturing and biotechnology. Peter Burke highlighted the broader economic and strategic significance of the investment, noting that it demonstrates how industry, innovation, and skilled talent can come together to drive high-value growth. He pointed out that facilities like Carrigaline are instrumental in translating research and innovation into scalable manufacturing capabilities, reinforcing Ireland’s competitiveness in global markets.
As demand for lactose-free and reduced-sugar dairy continues to accelerate across regions—including Europe, North America, and Asia-Pacific—Kerry’s enhanced production capacity is designed to help customers respond quickly and effectively. Consumers are increasingly seeking products that support digestive comfort while aligning with broader health and wellness goals, such as reduced sugar intake. Lactase enzymes play a critical role in enabling these product innovations, making their reliable supply essential for dairy manufacturers.
Ronan Moloney, Vice President of Enzymes at Kerry, emphasized that the expansion is as much about execution as it is about innovation. He explained that the increased capacity in Carrigaline, combined with Kerry’s deep application expertise, allows the company to guide customers through every stage of the production process. From selecting the right enzyme solution to optimizing processing conditions and scaling up production, Kerry aims to eliminate operational challenges and ensure consistent product quality.
The Carrigaline site itself serves as a cornerstone of Kerry’s global enzyme manufacturing network. It currently supports more than 200 customers across over 80 countries, highlighting its critical role in the company’s international operations. The lactase enzymes produced at the facility are used to process more than two million tonnes of milk annually, ultimately reaching an estimated 28 million consumers worldwide. These figures underscore the scale and impact of Kerry’s biotechnology solutions in the global dairy value chain.
With the expanded facility now fully operational, Kerry is well positioned to support the next phase of growth in the lactose-free and reduced-sugar dairy segments. The company’s integrated model—combining decades of expertise in dairy science with cutting-edge enzyme technology and large-scale manufacturing—enables it to act as a comprehensive partner for its customers. This holistic approach ensures that dairy producers can move seamlessly from concept development to commercial launch, backed by a reliable and scalable supply chain.
Looking ahead, Kerry’s investment in Carrigaline reflects broader trends shaping the food and beverage industry, including the increasing importance of biotechnology, sustainability, and health-focused innovation. By strengthening its capabilities in enzyme production and application, the company is not only meeting current market demands but also positioning itself to address future challenges and opportunities.
Ultimately, the expansion of the Carrigaline biotechnology facility underscores Kerry’s commitment to driving innovation at scale, supporting its customers with advanced solutions, and contributing to the evolution of the global dairy industry.
Source Link:https://www.kerry.com/
